by FRAN SVERDRUP, PHD St. Louis, Missouri DUX4 is considered to be a key cause of muscle degeneration in FSH muscular dystrophy. This is why we are interested in finding… Read More »
Placing a BET on blocking DUX4
Nearly $1.2 million committed in 2017 to FSH muscular dystrophy research
The FSH Society has awarded grants totaling $616,467 to seven research projects submitted during the February 2017 grant cycle. This brings the Society’s total new research commitments to $1,167,260 for… Read More »
A new DUX4 mouse with muscle disease
The FSH muscular dystrophy scientific literature finally has a publication describing a genetic mouse model that develops skeletal muscle disease. This work comes via the laboratory of Michael Kyba, PhD,… Read More »
Testosterone and human growth hormone clinical trial for FSHD
UPDATED October 30, 2017 Researchers at the University of Rochester in New York are conducting a research study to learn more about a potential symptomatic therapy for FSHD. This study… Read More »
An FSHD Antisense Therapy Primer
Q&A With Dr. Yi-Wen Chen by JIM ALBERT, Eldersburg, Maryland Antisense therapy is a form of treatment for genetic disorders. In the past year antisense drugs have been approved by the… Read More »